We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 574

Formulation patent found not to be infringed as a redacted excipient was not a “pentahydric or hexahydric alcohol”

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 22 2015

Apotex has successfully alleged that Teva’s patent to “Stable Compositions Containing Rasagiline” will not be infringed by Apotex’s use of a

Ramipril section 8 appeal dismissed from the bench by the Supreme Court of Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 22 2015

On Monday, April 20, 2015, the Supreme Court of Canada heard the appeal of 2014 FCA 68, relating to the issue of damages under section 8 of the

Court enforces a settlement agreement even though one party denied such an agreement existed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 22 2015

Allergan brought a motion to enforce a settlement agreement that Apotex denies was made. Allergan had sued for infringement and Apotex wrote a

PM(NOC) proceedings: Teva defeats VELCADE cancer treatment patent

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • April 17 2015

In reasons dated February 26, 2015, Justice Barnes dismissed Janssen's application for an order prohibiting the Minister of Health from issuing a

Pharma in brief - no induced infringement: patent struck from application under s. 6(5)(b) of the PM(NOC) Regulations

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • April 16 2015

Prothonotary Lafrenière issued an order pursuant to section 6(5)(b) of the PM(NOC) Regulations striking all allegations relating to one of

Pharma in brief - Generic v. Generic PM(NOC) application dismissed for non-infringement

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • April 21 2015

In a recently published Public Judgment and Reasons, Justice Gleason dismissed Teva Canada Innovation and Teva Pharmaceutical

Patent found valid and infringed even if the method of infringement was not in the minds of the inventors

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 13 2015

AstraZeneca sued Apotex for infringement of its patent relating to the formulation of the drug omeprazole. Apotex argued invalidity and

Methods of medical treatment and dosage claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada

Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer

Federal Court declares omeprazole formulation patent valid and infringed

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 25 2015

On March 16, 2015, Justice Barnes of the Federal Court issued his decision in AstraZeneca Canada Inc. et al v. Apotex Inc., 2015 FC 322, declaring